Podcasts about staphylococci

Researcher Brenda McManus is leading a microbiology study to better understand periodontal disease and foot ulcers in patients with diabetes. Offer: TRĒ House products are crafted to bring you the best that legal, delivered-to-your-door THC has to offer. TRĒ House utilizes unique blends of carefully selected minor cannabinoids that get you lit in ways you've only ever dreamed of. TRĒ House offers an array of premium, legal THC products including gummies, vapes, prerolls, and more. Head over to trehouse.com and enjoy 30% off your order AND get a free Acapulco Gold HHC preroll when you use coupon code GENIUS. This offer expires August 31, 2023. She explains her microbial research by discussing: How Staphylococcus aureus links molecular biology, periodontal disease, and foot ulcers; Why patients with diabetes are immunologically prone to these microbial vulnerabilities; and How she's identifying if the staph in the nose cavity is the same as that in the foot and next steps to find if it travels through the bloodstream or through contact. Dr. Brenda McManus is an Experimental Officer in Microbiology in the School of Dental Science at Trinity College in Dublin. She talks about her microbiology study involving dental health, foot ulcers, and diabetes with a focus on Staphylococci species. They've found bacteria in foot ulcers that “shouldn't be there,” and these same bacteria are present in periodontal disease. She establishes why patients who suffer from diabetes struggle with foot ulcers and periodontal disease, from such reasons as poor circulation or nerve damage from excess glucose.  This means they can't feel an injury to the foot or can't feel pain when a wound is developing. In addition, bacteria in periodontal disease can cause pockets in the gums and swelling and can ultimately lead to tooth loss. It is twice as common and more severe in people who have diabetes. She mentions additional research showing links between periodontal disease and other diseases throughout the body including heart and kidney disease. She describes her current research and says her team is comparing genomic sequences of different staph samples from the mouth, fingers, toes, and more, identifying which species are in each site. She adds that if they identify the same species in all the different sites, they will compare the isolate genomes. If they are the same, that would be very strong evidence that there is a link between these sites. She describes next steps, therapeutic goals, and the importance of awareness of periodontal health and disease prevention. For more, see her information on the Trinity College website, tcd.ie/research/profiles/?profile=bmcmanu, and find her on Research Gate and LinkedIn. Episode also available on Apple Podcasts: https://apple.co/30PvU9C

In this episode, Kyle Molina, PharmD, BCIDP, provides an overview of treatment of skin and soft tissue infections (SSTIs) and challenges in practice. Listen as he gives perspectives on:Guideline recommendations for treatment of purulent and nonpurulent SSTIsLogistical challenges with IV and oral antibioticsPros and cons of various locations of careData supporting the safety and efficacy of long-acting lipoglycopeptides for treatment of SSTIsUse of long-acting lipoglycopeptides in special populations of interest, including patients with obesity, diabetes, and injection drug useOverall place in therapy of long-acting lipoglycopeptides for SSTIs Faculty:Kyle Molina, PharmD, BCIDPInfectious Diseases Clinical PharmacistScripps Green HospitalLa Jolla, CaliforniaLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E

In this episode, Martin Krsak, MD, MSc, FASAM, provides background and context on skin and soft tissue infections. Listen as he gives perspectives on:Epidemiology and clinical outcomesEconomic impactBacterial etiologyImportance of appropriate antimicrobial prescribingClinical presentationSeverity classification and distinction between purulent and nonpurulent infectionsRole of incision and debridement vs antimicrobial managementComplications to be ruled out prior to treatmentFaculty:Martin Krsak, MD, MSc, FASAMAssociate Professor of MedicineDivision of Infectious Diseases University of Colorado School of MedicineDenver, ColoradoLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E

This is a panel discussion on mobile genetic elements, guest chaired by Dr Muhammad Yasir with guests Dr Emma Waters, Dr Heather Felgate and Dr Andrew Page. We cover AMR, Salmonella Typhi and Staphylococci and outbreaks and the role of MGEs. It was recorded in front of a live audience of PhD students at the Microbes, Microbiomes and Bioinformatics doctoral training program in the Quadram Institute in Norwich UK.

Dr. Jacqueline Sherbuk, Assistant Professor at the Morsani College of Medicine Division of Infectious Diseases, presents a review on several important classes of clinically significant gram-positive bacteria. Dr. Sherbuk begins by discussing Staphylococcus aureus, MRSA, and Coagulase negative Staphylococci and some of the clinical syndromes they can cause. Next, Dr. Sherbuk introduces Streptococcus pneumonia and the syndrome of invasive pneumococcal disease. Then, Group A strep pyogenes, the viridans streptococci, and the variant streptococci are related. Also presented are Enterococcus faecalis and vancomycin resistant enterococcus faecium. Lastly, Dr. Sherbuk references Corynebacterium spp., Listeria, Bacillus, and Erysipelothirx spp.

What are the coagulase negative Staphylococci (CNS)? In this episode of the ID:IOTS podcast Callum and his Jame coalesce their clinical knowledge of coagulase negative Staphylococci

Susceptibility testing for staphylococci other than S. aureus, or SOSA, has become increasingly complicated, as more laboratories use MALDI-TOF to routinely identify these bacteria to the species level. In particular, accurate identification of methicillin resistance has become more complex as the different species are distinguished by the accuracy of different susceptibility testing methods and breakpoints for interpreting MICs and zone sizes.  Some of the questions we’ll discuss include: What is the gold standard for detecting methicillin resistance in SOSA? How will the recommended breakpoints for detection of methicillin-resistant SOSA change? Why should we call these bacteria SOSA instead of coagulase-negative staphylococci? Guests: Dr. Romney Humphries, Dr. Lars Westblade Links mentioned: Evaluation of Surrogate Tests for the Presence of mecA-Mediated Methicillin Resistance in Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus warneri The End of Coagulase-Negative Staphylococci? A Micro-Comic Strip Subscribe to Editors in Conversation (free) on Apple Podcasts, Google Podcasts, Android, Spotify.

Researcher Brenda McManus is leading a microbiology study to better understand periodontal disease and foot ulcers in patients with diabetes. She explains her microbial research by discussing How Staphylococcus aureus links molecular biology, periodontal disease, and foot ulcers; Why patients with diabetes are immunologically prone to these microbial vulnerabilities; and How she's identifying if the staph in the nose cavity is the same as that in the foot and next steps to find if it travels through the bloodstream or through contact. Dr. Brenda McManus is an Experimental Officer in Microbiology in the School of Dental Science at Trinity College in Dublin. She talks about her microbiology study involving dental health, foot ulcers, and diabetes with a focus on Staphylococci species. They've found bacteria in foot ulcers that “shouldn't be there,” and these same bacteria are present in periodontal disease. She establishes why patients who suffer from diabetes struggle with foot ulcers and periodontal disease, from such reasons as poor circulation or nerve damage from excess glucose.  This means they can't feel an injury to the foot or can't feel pain when a wound is developing.  In addition, bacteria in periodontal disease can cause pockets in the gums and swelling and can ultimately lead to tooth loss. It is twice as common and more severe in people who have diabetes. She mentions additional research showing links between periodontal disease and other diseases throughout the body including heart and kidney disease. She describes her current research and says her team is comparing genomic sequences of different staph samples from the mouth, fingers, toes, and more, identifying which species are in each site. She adds that if they identify the same species in all the different sites, they will compare the isolate genomes. If they are the same, that would be very strong evidence that there is a link between these sites. She describes next steps, therapeutic goals, and the importance of awareness of periodontal health and disease prevention. For more, see her information on the Trinity College website, tcd.ie/research/profiles/?profile=bmcmanu, and find her on Research Gate and LinkedIn. Available on Apple Podcasts: apple.co/2Os0myK

#61 Dr. Vincent A. Fischetti (Phage bacteria, antibiotic resistance, coronavirus)  https://www.rockefeller.edu/our-scientists/heads-of-laboratories/1160-vincent-a-fischetti/ From the web:The Fischetti lab exploits the evolution of bacteria-killing viruses, known as phages, to develop new ways to prevent and treat bacterial infections. This strategy has revealed bacteria-killing enzymes and novel immunotherapies that can overcome antibiotic-resistant bacteria. Fischetti works with both gram-positive and gram-negative bacteria, such as streptococci, staphylococci, anthrax, and acinetobacter, to develop unique treatment strategies to prevent infection. His approach involves novel immunotherapies and the use of phage lytic enzymes to both prevent infection and remove pathogenic bacteria from infected tissues. Fischetti’s lab uses recombinantly produced phage lysins that will kill the major gram-positive and gram-negative pathogens including Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus, Clostridium difficile, Bacillus anthracis, and Acinetobacter baumannii. The enzymes are extremely potent; micrograms can destroy millions of organisms within seconds. They are also highly specific and, unlike antibiotics, only kill the disease-causing bacteria, without harming the beneficial bacteria. Fischetti’s studies have shown that when small amounts of phage lysins are administered to infected mice, disease-causing bacteria are rapidly destroyed. In an animal model of pneumococcal pneumonia, Fischetti and his collaborators have shown that systemic administration of the phage enzyme Cpl-1 can rescue infected mice and completely reverse lung tissue damage if given within 24 hours post-infection. Similarly, experiments involving antibiotic-resistant S. aureus causing serious bacteremia in mice returned similar results after treatment with a staphylococcal-specific lysin. This lysin technology has been licensed and is currently in human clinical trials. Using lytic enzymes as a tool, Fischetti’s lab developed a method of drilling through the thick cell walls of gram-positive bacteria while keeping the cells intact. The technique enabled the researchers to access the bacterial cytoplasm with labeled antibodies to study intracellular molecules that were previously inaccessible. As a result of the high variability and plasticity of S. aureus, vaccine development has been challenging and has yet to be accomplished. Using the high-affinity binding domain of phage lysins directed to S. aureus, the Fischetti lab has successfully developed fusion immunoglobulins (called lysibodies) with the capacity to bind to the common cell wall of all Staphylococci, resulting in efficient phagocytic killing by human white blood cells. Lysibodies may be used to boost the immune response of Staphylococcus-infected patients. Because bacteria use their surface molecules to attack and invade human tissues, a better understanding of how they anchor these molecules in their cell walls could lead to new strategies to prevent infection. The M surface protein is the major virulence factor of group A streptococci because of its ability to impede human white blood cells. Analysis by Fischetti’s lab shows that the region used to attach the M protein to the streptococcal cell surface is highly conserved in all gram-positive bacteria, indicating that the mechanism for anchoring surface proteins in bacteria is also conserved. Since bacteria cannot cause infection without surface proteins, a molecule that blocks surface protein attachment would be broadly applicable to different gram-positive bacteria.FOLLOW US:https://www.facebook.com/mindmeltpodcast/https://www.instagram.com/mindmeltpodcast/

Bacteriophages -- viruses that target and kill bacteria -- were one of the most promising medical treatments of the early 20th century, and were used to treat all sorts of infections, from cholera to staph, and everything in between. But by the 1950s, they had all but died out in the West. This episode tells the story of the humble phage, from its discovery in the waters of the Ganges, love trysts ending in a KGB execution, and to a resurgence of this once forgotten therapy in the 21st century as an answer to antibiotic resistance. Sources:   Abedon ST, Bacteriophage prehistory: Is or is not Hankin, 1896, a phage reference? Bacteriophage. 2011 May-Jun; 1(3): 174–178. Blair JE and Williams REO, “Phage Typing of Staphylococci,” Bull Org mond. Ste, 1961, 24, 771-784. Davis BM and Waldor MK, Filamentous phages linked to virulence of Vibrio cholera, Current Opinion in Microbiology 2003, 6:35-42. d’Herelle F, “Bacteriophage as a treatment in acute medical and surgical infections,” Bull N Y Acad Med. 1931 May; 7(5): 329–348. d'Herelle F.  Sur un microbe invisible antagoniste des baccilles dysenteriques.  CR Acad Sci Paris 1917,163,173-5. Eaton MD, Bayne-Jones S. Bacteriophage Therapy. JAMA 1934; 103:1769-76; 1847-53; 1934-9. Fruciano DE and Bourne S, Phage as an antimicrobial agent: d’Herelle's heretical theories and their role in the decline of phage prophylaxis in the West, Can J Infect Dis Med Microbiol. 2007 Jan; 18(1): 19–26 Hankin EH.  L'action bactericide des eaux de la Jumna at du Gange sur le vibrion du cholere. Ann Int Pasteur (Paris) 1896,10,511-23. Himmelweit F. Combined action of penicillin and bacteriophage on Staphylococci. Lancet. 1945;ii:104. Hicks DJ et al, “Developments in rabies vaccines,” Clin Exp Immunol. 2012 Sep; 169(3): 199–204. Kingwell K, Bacteriophage therapies re-enter clinical trials, Nature, Vol 14, Aug 2015, 515. Jensen MA et al, Modeling the role of bacteriophage in the control of cholera outbreaks, Proc Natl Acad Sci U S A. 2006 Mar 21; 103(12): 4652–4657. Hargreaves KR and Clokie MRJ, Clostridium difficile phages: still difficult? Front Microbiol. 2014 Apr 28;5:184. La Fee S and Buschman H, Novel Phage Therapy Saves Patient with Multidrug-Resistant Bacterial Infection. Retrieved from: https://health.ucsd.edu/news/releases/Pages/2017-04-25-novel-phage-therapy-saves-patient-with-multidrug-resistant-bacterial-infection.aspx Leitner L et al, Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 2017 Sep 26;17(1):90. Pearce J, Louis Pasteur and Rabies: a brief note, Journal of Neurology, Neurosurgery & Psychiatry 2002;73:82. Schooley et al, Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection. Antimicrobial Agent and Chemotherapy, 14 Aug 2017. Strathdee S, How Sewage Saved My Husband's Life from a Superbug, TEDxNashville, retrieved from: https://www.youtube.com/watch?v=AbAZU8FqzX4. Summers WC, Bacteriophage Therapy, Annual Review of Microbiology, Vol. 55:437-451 (Volume publication date October 2001) Summers WC, The strange history of phage therapy. Bacteriophage. 2012 Apr 1; 2(2): 130–133. Taylor M.W. (2014) Introduction: A Short History of Virology. In: Viruses and Man: A History of Interactions. Springer, Cham Thiel, K. (2004). Old dogma, new tricks—21st Century phage therapy. Nature Biotechnology, 22(1), 31–36. Twort FW, An investigation on the nature of Ultra-Microscopic Viruses, The Lancet, Jan 10th, 1914. 101. Wittebole X et al, A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014 Jan 1; 5(1): 226–235. Ujmajuridze et al, Adapted Bacteriophages for Treating Urinary Tract Infections. Front Microbiol. 2018; 9: 1832. Ventola CL, “The Antibiotic Resistance Crisis: Part 1: Causes and Threats,” P T. 2015 Apr; 40(4): 277–283.

It’s our first episode with a special guest! We take a look at the Simpsons episode “Bart the Genius”. Tom has a revelation about the “Staphylococci virus”, Garreth tells us about all things banana related, and we are joined by Simon Singh, author of “The Simpsons and their Mathematical Secrets” to talk about the maths… Read More »

Vincent, Michael, Elio, and Joe review highlights of the 15th International Symposium on Staphylococci and Staphylococcal Infections (ISSSI) in Lyon, France.

Staphylococci in the facemasks of workers in mince-meat-production by the example of two southern German meat factories In this study a microbiological survey was made about facemasks taken from two EU-accredited meat processing factories in southern Germany. In factory A 110 masks from 44 meat workers were examined. This examination took place between April 2002 and January 2003. For comparison 51 masks of one day of production were taken in factory B. For both factories a survey was made of the bacterial flora, particularly regarding the coagulase-positive staphylococci which were contained in facemasks used during the processing of mince meat. The masks which went into the examination were compulsively used by all the staff of the mince-meat-production including dissection. At factory A 43% of the persons belonging to the mince meat processing, whose masks were examined were carriers of coagulase-positive staphylococci, compared to 64% at factory B. But the statistical spread of results, especially for coagulase-positive staphylococci, was significantly higher at factory A than at factory B. The results of the facemask of certain workers at this factory were also comparatively higher. There were also detectable interrelations between the total plate count and coagulase-positive staphylococci and the function and gender of the meat workers. Meanwhile there were no detectable interrelations between bacterial counts and possible seasonal influences. Despite of remarkably high results found in the facemasks of separate meat workers no negative influences on the microbial quality of the mince meat could be observed, which makes the wearing of facemasks in mince meat production appear to be a simple way of avoiding contamination. If it is not possible to provide a good hygienic management or if separate staphylococcal isolates occur in the facemasks of certain meat workers as well as in the corresponding mince meat, an intranasal treatment with mupirocin could be considered for these persons. An noncritical application of antibiotics is not recommended due to the risk of creating resistances.